CRISPR Therapeutics, ViaCyte dose type 1 diabetes patient with new cell therapy

By The Science Advisory Board staff writers

February 4, 2022 -- CRISPR Therapeutics and ViaCyte have dosed the first patient with VCTX210 in a phase I clinical trial for the treatment of type 1 diabetes (T1D).

VCTX210 is an investigational, allogeneic, gene-edited, stem cell-derived product that applies CRISPR Therapeutics' gene editing technology to ViaCyte's proprietary stem cell capabilities for the generation of pancreatic cells designed to evade recognition by the immune system. This immune-evasive cell replacement therapy is designed to enable patients to produce their own insulin.

The phase I clinical trial of VCTX210 will assess its safety, tolerability, and immune evasion in patients with T1D. This program is being advanced by CRISPR Therapeutics and ViaCyte as part of a strategic collaboration to discover, develop, and commercialize gene-edited, stem cell-derived therapies that could offer a functional cure for people living with T1D and insulin-requiring type 2 diabetes without the need for immunosuppression.

CRISPR Therapeutics is a biopharmaceutical company focused on developing gene-based medicines for serious diseases. ViaCyte is a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs.

Copyright © 2022

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.